117 related articles for article (PubMed ID: 9454886)
1. CDKN2/p16 inactivation and p16 immunohistochemistry in astrocytic gliomas.
Piva R; Cavalla P; Bortolotto S; Cordera S; Grosso R; Richiardi P; Dutto A; Schiffer D
Int J Oncol; 1998 Jan; 12(1):55-8. PubMed ID: 9454886
[TBL] [Abstract][Full Text] [Related]
2. Malignant astrocytomas with homozygous CDKN2/p16 gene deletions have higher Ki-67 proliferation indices.
Ono Y; Tamiya T; Ichikawa T; Kunishio K; Matsumoto K; Furuta T; Ohmoto T; Ueki K; Louis DN
J Neuropathol Exp Neurol; 1996 Oct; 55(10):1026-31. PubMed ID: 8857999
[TBL] [Abstract][Full Text] [Related]
3. EZH2 expression in gliomas: Correlation with CDKN2A gene deletion/ p16 loss and MIB-1 proliferation index.
Purkait S; Sharma V; Jha P; Sharma MC; Suri V; Suri A; Sharma BS; Sarkar C
Neuropathology; 2015 Oct; 35(5):421-31. PubMed ID: 26096306
[TBL] [Abstract][Full Text] [Related]
4. Alterations of retinoblastoma, p53, p16(CDKN2), and p15 genes in human astrocytomas.
Tsuzuki T; Tsunoda S; Sakaki T; Konishi N; Hiasa Y; Nakamura M
Cancer; 1996 Jul; 78(2):287-93. PubMed ID: 8674005
[TBL] [Abstract][Full Text] [Related]
5. CDKN2/p16 predicts survival in oligodendrogliomas: comparison with astrocytomas.
Miettinen H; Kononen J; Sallinen P; Alho H; Helen P; Helin H; Kalimo H; Paljärvi L; Isola J; Haapasalo H
J Neurooncol; 1999 Feb; 41(3):205-11. PubMed ID: 10359140
[TBL] [Abstract][Full Text] [Related]
6. Silencing of p16/CDKN2 expression in human gliomas by methylation and chromatin condensation.
Costello JF; Berger MS; Huang HS; Cavenee WK
Cancer Res; 1996 May; 56(10):2405-10. PubMed ID: 8625319
[TBL] [Abstract][Full Text] [Related]
7. Alteration of CDKN2/p16 in human astrocytic tumors is related with increased susceptibility to antimetabolite anticancer agents.
Iwadate Y; Mochizuki S; Fujimoto S; Namba H; Sakiyama S; Tagawa M; Yamaura A
Int J Oncol; 2000 Sep; 17(3):501-5. PubMed ID: 10938390
[TBL] [Abstract][Full Text] [Related]
8. CDKN2/p16 or RB alterations occur in the majority of glioblastomas and are inversely correlated.
Ueki K; Ono Y; Henson JW; Efird JT; von Deimling A; Louis DN
Cancer Res; 1996 Jan; 56(1):150-3. PubMed ID: 8548755
[TBL] [Abstract][Full Text] [Related]
9. Homozygous deletion of the p16/MTS-1/CDKN2 gene in malignant gliomas is infrequent among Japanese patients.
Mochizuki S; Iwadate Y; Namba H; Yoshida Y; Yamaura A; Sakiyama S; Tagawa M
Int J Oncol; 1999 Nov; 15(5):983-9. PubMed ID: 10536183
[TBL] [Abstract][Full Text] [Related]
10. Hypermethylation of the CpG island of p16/CDKN2 correlates with gene inactivation in gliomas.
Fueyo J; Gomez-Manzano C; Bruner JM; Saito Y; Zhang B; Zhang W; Levin VA; Yung WK; Kyritsis AP
Oncogene; 1996 Oct; 13(8):1615-9. PubMed ID: 8895506
[TBL] [Abstract][Full Text] [Related]
11. Deletion analysis of the p16/CDKN2 gene in head and neck squamous cell carcinoma using quantitative polymerase chain reaction method.
Rawnsley JD; Srivatsan ES; Chakrabarti R; Billings KR; Wang MB
Arch Otolaryngol Head Neck Surg; 1997 Aug; 123(8):863-7. PubMed ID: 9260553
[TBL] [Abstract][Full Text] [Related]
12. Correlative immunohistochemistry and molecular genetic study of the inactivation of the p16INK4A genes in astrocytomas.
Rao LS; Miller DC; Newcomb EW
Diagn Mol Pathol; 1997 Apr; 6(2):115-22. PubMed ID: 9098651
[TBL] [Abstract][Full Text] [Related]
13. MTS1/p16/CDKN2 lesions in primary glioblastoma multiforme.
Moulton T; Samara G; Chung WY; Yuan L; Desai R; Sisti M; Bruce J; Tycko B
Am J Pathol; 1995 Mar; 146(3):613-9. PubMed ID: 7887443
[TBL] [Abstract][Full Text] [Related]
14. Alterations of the cyclin D1/p16-pRB pathway in mantle cell lymphoma.
Dreyling MH; Bullinger L; Ott G; Stilgenbauer S; Müller-Hermelink HK; Bentz M; Hiddemann W; Döhner H
Cancer Res; 1997 Oct; 57(20):4608-14. PubMed ID: 9377576
[TBL] [Abstract][Full Text] [Related]
15. Analysis of a role for p16/CDKN2 expression and methylation patterns in human oral squamous cell carcinoma.
Yakushiji T; Noma H; Shibahara T; Arai K; Yamamoto N; Tanaka C; Uzawa K; Tanzawa H
Bull Tokyo Dent Coll; 2001 Aug; 42(3):159-68. PubMed ID: 11806150
[TBL] [Abstract][Full Text] [Related]
16. p16/CDKN2 alterations and pRb expression in oesophageal squamous carcinoma.
Busatto G; Shiao YH; Parenti AR; Baffa R; Ruol A; Plebani M; Rugge M
Mol Pathol; 1998 Apr; 51(2):80-4. PubMed ID: 9713590
[TBL] [Abstract][Full Text] [Related]
17. CDKN2 (p16/MTS1) gene deletion or CDK4 amplification occurs in the majority of glioblastomas.
Schmidt EE; Ichimura K; Reifenberger G; Collins VP
Cancer Res; 1994 Dec; 54(24):6321-4. PubMed ID: 7987821
[TBL] [Abstract][Full Text] [Related]
18. Genetic heterogeneity in human astrocytomas: spatial distribution of P16 and TP53 deletions in biopsies.
Steilen-Gimbel H; Steudel WI; Feiden W; Moringlane JR; Henn W; Zang KD
Cancer Genet Cytogenet; 1999 Sep; 113(2):115-9. PubMed ID: 10484976
[TBL] [Abstract][Full Text] [Related]
19. Prognostic value of the expression of tumor suppressor genes p53, p21, p16 and prb, and Ki-67 labelling in high grade astrocytomas treated with radiotherapy.
Kirla R; Salminen E; Huhtala S; Nuutinen J; Talve L; Haapasalo H; Kalimo H
J Neurooncol; 2000; 46(1):71-80. PubMed ID: 10896207
[TBL] [Abstract][Full Text] [Related]
20. Alterations of p16-pRb pathway and chromosome locus 9p21-22 in sporadic invasive breast carcinomas.
Gorgoulis VG; Koutroumbi EN; Kotsinas A; Zacharatos P; Markopoulos C; Giannikos L; Kyriakou V; Voulgaris Z; Gogas I; Kittas C
Mol Med; 1998 Dec; 4(12):807-22. PubMed ID: 9990866
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
